Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Revenue Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) Revenue Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 5.42%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 15.35%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn 0.71%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -1.79%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -2.20%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -36.99%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 6.64%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -13.59%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -1.79%
Mar 28, 2026 -1.10%
Dec 27, 2025 -3.31%
Sep 27, 2025 0.53%
Jun 28, 2025 1.98%
Mar 29, 2025 2.50%
Dec 28, 2024 3.47%
Sep 28, 2024 4.07%
Jun 29, 2024 3.91%
Mar 30, 2024 7.05%
Dec 30, 2023 8.61%
Sep 30, 2023 11.37%
Jul 1, 2023 15.80%
Apr 1, 2023 13.34%
Dec 31, 2022 16.75%
Sep 24, 2022 13.98%
Jun 25, 2022 13.96%
Mar 26, 2022 14.77%
Dec 25, 2021 14.59%
Sep 25, 2021 15.25%